ArticleArchives of microbiology2026
WGS analysis and functional studies illustrate promising gene-signatures for probiotic attributes and molecular-targeted therapeutic prospects of Lactiplantibacillus plantarum LP-ARP2.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene-signatures for probiotic attributes expedite screening of novel probiotic strains as well as identify molecular basis of probiotic benefits. Therefore, strain-specific genomic-studies correlating functional-assays are in demand. Here, we present the same for Lactiplantibacillus plantarum LP-ARP2 using genomic-metabolomic-functional approaches. Genomic-features of LP-ARP2 are further compared with clinically relevant L. plantarum strains to elucidate gene-specific commonality. We find robust stress-resilience genetic set-up (usp/hsl/clp/ABC-transporters/ ATP-synthase/chaperons dna/gro/grp) in LP-ARP2-genome. Our acid/bile tolerance assays also indicate survivability (> 60%) of the strain in harsh conditions. Presence of adhesion-related (lspA/mapA/eno/srtA/glycosyltransferases/glycosylhydrolases/lipoproteins) and biofilm-forming genes (veg/luxS) further align with its efficacy in autoaggregation (> 60%), adhesion (Caco-2), and biofilm-formation (24 h). CAZyme-genes with significant prebiotic utilization indicate the strain's ability for gut-microbial-modulation and adaptation. Metabolic-profiling of LP-ARP2-derived-CFS (HRMS analysis) validates the presence of related genes for SCFAs/vitamins/amino-acids/neurotransmitters GABA/serotonin/acetylcholine etc. Besides, many metabolites are reported antimicrobials. Indeed LP-ARP2 shows significant antibacterial potential against multidrug-resistant bacteria (Gram-positive/Gram-negative), gut-pathogen Salmonella Typhimurium and pathogenic-biofilm (MRSA). Presence of antioxidant-genes in LP-ARP2-genome (thioredoxin/NADH-dependent-nox/npr/ndh/glutathione-reductase/glutaredoxin/catalase/peroxidases/methionine sulfoxide reductase) are validated by high radical-scavenging activity of LP-ARP2 (ABTS > 40%, DPPH 25 U/mL, superoxide > 80%, and hydroxyl > 70%). Moreover, in-silico functional-network-analysis reveals LP-ARP2-derived metabolites target oxidative stress, neuroinflammation, amyloid-beta metabolism, tau-phosphorylation, neurogenesis, and synaptic function, indicating molecular relevance of the therapeutic potential of LP-ARP2. Fascinatingly, genomic-analysis between LP-ARP2 with clinically relevant (depression and intestinal disorders) L. plantarum strains (299v and Lp01) elucidate comparable genetic-features for beneficial probiotics. Thus, study offers potential gene-signatures for probiotic-benefits of L. plantarum and project LP-ARP2 as a promising probiotic with antibacterial, antioxidant and psychobiotic potential.
Indexed as
Identifiers
41553530What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.